Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKstar study of belumosudil in chronic graft-versus-host disease after at least 2 prior systemic therapies
2024-000203-67Phase 2
- Sponsor
- Kadmon
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Kadmon. Primary endpoint: Overall Response Rate.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2024-000203-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000203-67.